Location History:
- Winnipeg, CA (1999)
- Manitoba, CA (1999)
Company Filing History:
Years Active: 1999
Title: Genevieve Delcuve: Innovator in Recombinant DNA Technology
Introduction
Genevieve Delcuve is a prominent inventor based in Winnipeg, Canada. She has made significant contributions to the field of biotechnology, particularly in the development of recombinant DNA molecules and expression vectors. Her work has the potential to advance medical research and therapeutic applications.
Latest Patents
Genevieve holds 2 patents related to recombinant DNA technology. Her latest patents include innovations in recombinant DNA molecules and expression vectors for tissue plasminogen and erythropoietin. The first patent describes a recombinant DNA molecule designed for transfection of host cells, which encodes mammalian erythropoietin or tissue plasminogen activator. This invention includes an expression control sequence and at least one SAR element, enabling mammalian cells to express recombinant EPO or tPA at significant levels in vitro. The second patent focuses on a similar recombinant DNA molecule for erythropoietin, emphasizing its capability to express EPO in vitro at comparable levels.
Career Highlights
Genevieve is currently employed at Cangene Corporation, where she continues to innovate in the field of biotechnology. Her work at the company has positioned her as a key player in the development of advanced therapeutic solutions.
Collaborations
Genevieve collaborates with her coworker, Gregor Awang, to further enhance their research and development efforts in recombinant DNA technology.
Conclusion
Genevieve Delcuve's contributions to recombinant DNA technology exemplify her dedication to advancing biotechnological innovations. Her patents reflect her expertise and commitment to improving medical research and therapeutic applications.